Neuron Guard s.r.l.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Neuron Guard s.r.l. - overview
Established
2013
Location
Modena, -, Italy
Primary Industry
Medical Devices & Equipment
About
Neuron Guard s. r. l. develops advanced medical devices focused on portable cerebral targeted temperature management, specifically catering to acute brain injuries through innovative cooling solutions.
Founded in 2013 and headquartered in Modena, Italy, Neuron Guard s. r. l. specializes in medical technology.
The company has secured a total of EUR 0. 55 mn through three funding deals, with the latest round being a Venture Debt of EUR 0. 65 mn led by CDP Venture Capital in November 2021. Mary Franzese is the founder, while Enrico Giuliani serves as CEO.
Neuron Guard specializes in the development and manufacturing of innovative medical devices aimed at delivering selective and portable cerebral targeted temperature management. Their flagship product, the CB240_AURORA, is designed to provide targeted hypothermia to the brain by cooling the blood flow while minimizing systemic complications such as pneumonia. This device features a user-friendly interface that optimizes nursing workloads and employs a miniaturized, high-power heat pump system alongside a biocompatible thermal interface. Neuron Guard's solutions are particularly valuable in emergency medical settings, addressing acute brain injuries (ABI) including strokes and traumatic brain injuries across North America and Europe, where the demand for effective, efficient, and portable medical devices continues to rise.
The company's clientele encompasses hospitals, emergency medical services, and healthcare providers who seek advanced technologies to enhance patient care. Neuron Guard's revenue generation strategy is centered on direct sales and partnerships with healthcare institutions that require advanced medical solutions for the management of acute brain injuries. The company engages in transactions primarily on a B2B basis, supplying their CB240_AURORA device to hospitals and emergency medical services. In 2023, the company reported a revenue of EUR 188,928.
80 with an EBITDA of EUR -9,974. 30, demonstrating the ongoing demand for their specialized medical offerings. Neuron Guard intends to utilize the EUR 650,000 raised in the recent Venture Debt funding to achieve critical market milestones and enhance their appeal for future industrial agreements. The firm is focused on expanding the reach of the CB240_AURORA and is exploring additional product development aimed at enhancing their technology.
Furthermore, they are aiming for market expansion into broader regions across Europe and North America by 2024.
Current Investors
CDP Venture Capital, A11 Venture
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Supplies, Monitoring Equipment, Therapeutic Devices
Website
www.neuronguard.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Neuron Guard s.r.l. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 10,000 | - | 1,306 | - | - | 88,800 | 11,000 | 1,948 | 8,802 | - | - | - |
| % Revenue Growth (YoY) | - | (100.0%) | - | (100.0%) | - | - | (87.6%) | (82.3%) | 351.8% | - | - | - |
| EBITDA (USD) | (3,038) | (45,376) | (170,323) | (98,515) | (91,358) | 1,478 | (92,623) | (117,278) | (176,030) | - | - | - |
| Operating Income (USD) | (6,385) | (61,918) | (205,157) | (136,897) | (131,664) | (41,848) | (121,786) | (128,848) | (185,680) | - | - | - |
| Operating Margin | (63.9%) | - | (15708.8%) | - | - | (47.1%) | (1107.1%) | (6614.4%) | (2109.5%) | - | - | - |
| % EBITDA Margin | (30.4%) | - | (13041.6%) | - | - | 1.7% | (842.0%) | (6020.4%) | (1999.9%) | - | - | - |
| NET Income (USD) | (6,386) | (63,377) | (155,403) | (114,580) | (133,029) | (43,225) | (122,053) | (128,847) | (185,675) | - | - | - |
| % Net Margin | (63.9%) | - | (11899.2%) | - | - | (48.7%) | (1109.6%) | (6614.3%) | (2109.5%) | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.